血清IL-12、SAA水平对ST段抬高型心肌梗死患者PCI治疗预后的影响

承德医学院学报 ›› 2022, Vol. 39 ›› Issue (2): 110-113.

血清IL-12、SAA水平对ST段抬高型心肌梗死患者PCI治疗预后的影响

郭晓童

河南省商丘市中医院心内一科,河南商丘 476000

收稿日期:2021-09-03 出版日期:2022-04-10 发布日期:2022-07-29

Effect of Serum IL-12 and SAA Levels on the Prognosis of Patients with ST Segment Elevation Myocardial Infarction after PCI

GUO Xiao-tong

First Department of Cardiology, Shangqiu Hospital of Traditional Chinese Medicine of Henan Province, Shangqiu, Henan, 476000, China

Received:2021-09-03 Online:2022-04-10 Published:2022-07-29

摘要/Abstract

摘要： 目的观察血清白细胞介素-12（IL-12）、淀粉样蛋白A（SAA）在ST段抬高型心肌梗死（STEMI）患者中的表达,并分析其对STEMI患者行经皮冠状动脉介入（PCI）治疗预后的影响。方法选取2019年5月~2021年5月河南省商丘市中医院院收治的62例STEMI患者为研究对象,均于该院行PCI治疗,且术后获得1个月随访结果。随访1个月时,行冠状动脉造影检查评估患者冠状动脉管腔狭窄情况作为短期预后观察指标,并将其分为预后不良组与预后良好组;于患者入院时检测血清IL-12、SAA水平,询问并记录患者基线资料,分析血清IL-12、SAA水平对STEMI患者PCI治疗预后的影响。结果预后不良组术前血清IL-12、SAA水平均高于预后良好组,差异有统计学意义（P<0.05）;经Logistic回归分析结果显示,术前血清IL-12、SAA过表达对STEMI患者PCI治疗预后不良存在一定影响（P<0.05）。结论血清IL-12、SAA过表达对STEMI患者PCI治疗预后不良存在一定影响。

关键词: ST段抬高型心肌梗死, 经皮冠状动脉介入, 白细胞介素-12, 淀粉样蛋白A

Abstract: Objective To observe the expression of serum interleukin-12 (IL-12) and amyloid A (SAA) in patients with ST segment elevation myocardial infarction (STEMI), and to analyze its impact on the prognosis of STEMI patients after percutaneous coronary intervention (PCI). Methods Sixty-two patients with STEMI treated in Shangqiu Hospital of Traditional Chinese Medicine of Henan Province from May 2019 to May 2021 were selected as the research subjects, all patients were treated with PCI in our hospital and gained results of 1 month of follow-up after operation. At 1 month of follow-up, coronary angiography was performed to evaluate the coronary stenosis of patients, as a short-term prognostic indicator. The patients were divided into a poor prognosis group and a good prognosis group and serum levels of IL-12 and SAA were detected of patients at admission, asked and recorded the baseline data of patients. The influence of serum IL-12 and SAA levels on the prognosis of STEMI patients after PCI was analyzed. Results The serum levels of IL-12 and SAA in the poor prognosis group were higher than those in the good prognosis group, with a statistical significant difference (P<0.05); through Logistic regression analysis, the results showed that the overexpression of preoperative serum IL-12 and SAA had a certain impact on the poor prognosis of STEMI patients after PCI (P<0.05). Conclusion The overexpression of serum IL-12 and SAA has certain influence on the poor prognosis of STEMI patients after PCI.

Key words: ST segment elevation myocardial infarction, percutaneous coronary intervention, interleukin-12, amyloid A

中图分类号:

R542.22

郭晓童. 血清IL-12、SAA水平对ST段抬高型心肌梗死患者PCI治疗预后的影响[J]. 承德医学院学报, 2022, 39(2): 110-113.

GUO Xiao-tong. Effect of Serum IL-12 and SAA Levels on the Prognosis of Patients with ST Segment Elevation Myocardial Infarction after PCI[J]. Journal of Chengde Medical University, 2022, 39(2): 110-113.

参考文献

[1] 张文兴,朱莉. ST段抬高型心肌梗死治疗的研究进展[J]. 实用心脑肺血管病杂志,2017,25(10):4-7.
[2] 戴美凤,沈彬,陆传新,等. 直接PCI治疗急性ST段抬高型心肌梗死患者的近期预后及相关因素分析[J]. 心血管康复医学杂志,2017,26(3):273-276.
[3] 王阳,米树华,杨关林. 动脉粥样硬化机制研究进展[J]. 中国医药,2017,12(4): 619-623.
[4] 马元婧,邱润泽,袁冬平,等. 动脉粥样硬化中炎症免疫反应的研究进展[J]. 现代免疫学,2017,37(6):509-512.
[5] 郭利,戴楠. 冠状动脉疾病患者血清IL-12、IL-35水平与ox-LDL及冠状动脉狭窄程度的关系[J]. 中国临床研究,2018,31(9):1178-1181.
[6] 曹琳,宋晓文,任金来,等. 血清淀粉样蛋白A的研究进展[J]. 安徽医药,2019,23(2):221-224.
[7] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会. 急性ST段抬高型心肌梗死诊断和治疗指南[J]. 中华心血管病杂志,2015,43(5):380-393.
[8] 中华医学会心血管病学分会介入心脏病学组,中国医师协会心血管内科医师分会血栓防治专业委员会,中华心血管病杂志编辑委员会. 中国经皮冠状动脉介入治疗指南2016[J]. 中华心血管病杂志,2016,44(5):382-400.
[9] 杨泉,杨勇,余建群,等. 冠状动脉CT造影狭窄程度预测患者远期预后的临床价值研究[J]. 中国全科医学,2020,23(12):1492-1496,1503.
[10] 刘红娜,张悟棠,安健,等. 炎症因子与急性冠脉综合征相关性研究[J]. 中国心血管病研究,2017,15(2):150-153.
[11] 唐晓晏,申子刚,张志仁,等. 炎症消退障碍与动脉粥样硬化不稳定斑块形成[J]. 免疫学杂志,2017,33(4):364-368.
[12] 谷楠,李靓,孙勇,等. 动脉粥样硬化与炎症关系研究的进展[J]. 心血管康复医学杂志,2020,29(6):714-717.
[13] 袁峰,任秀华,徐凤忠. ST段抬高型心肌梗死患者SAA、NO水平与冠状动脉病变程度及预后的关系[J]. 安徽医学,2020,41(1):50-53.
[14] 韩月,朱莉,宋桂仙. 白介素-12家族在冠状动脉粥样硬化中的研究进展[J]. 心血管病学进展,2020,41(5):508-512.
[15] 张璐璐,刘芸,段文冰,等. 血清淀粉样蛋白A与冠心病的相关性研究[J]. 新医学,2019,50(1):11-15.